Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects

Potential Xarelto Successor Prioritized

Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.

Bayer aerial
• Source: Bayer

Bayer AG has confirmed that of the three projects in its Factor XIa program, the full focus is now on the oral treatment asundexian, ahead of two partnered therapies – fesomersen and osocimab – which had also shown potential in mid-stage trials.

Asundexian is positioned as the next-generation Xarelto (rivaroxaban), the firm's blockbuster Factor Xa blood thinner, and Bayer CEO Werner Baumann...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.